New Zealand markets closed

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.7700-0.0800 (-2.08%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 79.71M
Enterprise value 62.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.57
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.54

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3167.76%
S&P500 52-week change 326.49%
52-week high 37.4200
52-week low 31.0100
50-day moving average 35.0928
200-day moving average 33.2433

Share statistics

Avg vol (3-month) 390.8k
Avg vol (10-day) 372.18k
Shares outstanding 521.14M
Implied shares outstanding 621.14M
Float 88.22M
% held by insiders 10.65%
% held by institutions 123.45%
Shares short (30 Apr 2024) 4135.93k
Short ratio (30 Apr 2024) 40.89
Short % of float (30 Apr 2024) 40.90%
Short % of shares outstanding (30 Apr 2024) 40.81%
Shares short (prior month 28 Mar 2024) 435.34k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 311 Nov 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.94%
Return on equity (ttm)-34.21%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -18.43M
Net income avi to common (ttm)-18.07M
Diluted EPS (ttm)-3.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.04M
Total cash per share (mrq)1.45
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.82
Book value per share (mrq)5.39

Cash flow statement

Operating cash flow (ttm)-20.42M
Levered free cash flow (ttm)-8.97M